Netherlands· NL-e51d6fae5394
Evista 60 mg, omhulde tabletten
A raloxifene product containing raloxifeenhydrochloride, registered in Netherlands by Substipharm. The same ATC class is registered in 19 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Raloxifene is registered in 19 of 19 countries.
Countries holding a registration under ATC G03XC01 (raloxifene), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 11 of them publish a price we can compare per daily dose
Raloxifene · ATC G03XC01
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of raloxifene costs, country by country.
Normalised to the WHO defined daily dose (60 mg), the median price runs from $0.44 in France to $1.28 in Switzerland — a ×2.9 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Raloxifene · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.28
- ES Spain$0.84
- IT Italy$0.70
- FR France$0.44
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- RALOXIFEENHYDROCHLORIDE
- Manufacturer
- Substipharm
- Country
- Netherlands (NL)
- ATC code
- G03XC01
- ATC class
- Raloxifene
- Defined daily dose
- 60 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/98/073
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
183 interactions on record for raloxifene.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Raloxifene · interactions on record
183 records
- 8 severe
- 12 moderate
- 6 minor
- 157 info
Most severe, free to view
- Tranexamic acidB02AA02severe
- BexaroteneL01XF03severe
- CarfilzomibL01XG02severe
- BexarotenL01XX25severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Raloxifene in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United Statesraloxifene hydrochlorideGlenmark Pharmaceuticals Inc., USA
- SpainEVISTA 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULASubstipharm
- CzechiaEVISTASubstipharm, Paris
- FranceEVISTA 60 mg, comprimé pelliculéSUBSTIPHARM
- IrelandEvista 60 mg film coated tabletsSubstipharm
- SwedenEvista 60 mg Filmdragerad tablettSubstipharm
- BelgiumOptruma 60 mgEli Lilly Nederland
- FinlandEvistaParanova Oy
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Raloxifen Stada
- Cyprus · Ostiral
- Germany · Raloxifen Al, Raloxifen-Hcl Hexal
- Spain · Raloxifeno Aurovitas, Raloxifeno Cinfamed
- France · Raloxifene Arrow, Raloxifene Biogaran
- United Kingdom (Northern Ireland) · Evirex, Ostiral
- Greece · Ostiral
- Hungary · Clastellos, Raloxibone
- Iceland · Evista, Optruma
- Italy · Raloxifene Sandoz
- Liechtenstein · Evista, Optruma
- Norway · Evista, Optruma
- Portugal · Raloxifeno Ciclum, Raloxifeno Exeltis
- Romania · Raloxifen Arena
- Sweden · Raloxifen Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8291f113-5e47-49a2-bfe3-12c3f70d7e77 GET /v1/drugs/8291f113-5e47-49a2-bfe3-12c3f70d7e77?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/evista-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Raloxifene",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp70245",
"excipients": [
"CROSPOVIDON (E 1202)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"LACTOSE 0-WATER",
"LACTOSE 1-WATER",
"MACROGOL 400",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYSORBAAT 80 (E 433)",
"POVIDON (E 1201)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"RALOXIFEENHYDROCHLORIDE"
],
"leaflet_url": null,
"authorised_at": "1998/08/05",
"procedure_number": "EMEA/H/C/000184",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/98/073",
"additional_monitoring": "N"
}See everything about raloxifene.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.